Novonesis (CPSE:NSIS B) - Stock Price, News & Analysis

NSIS B Stock Overview

Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally.

About the company

NSIS B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 28.86% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Large one-off items impacting financial results

Profit margins (9.3%) are lower than last year (19.3%)

Novonesis A/S Competitors

Wanhua Chemical Group

SHSE:600309

CN¥253.4b

Asian Paints

NSEI:ASIANPAINT

₹3.1t

PPG Industries

NYSE:PPG

US$29.8b

DuPont de Nemours

NYSE:DD

US$35.9b

Price History & Performance

Summary of all time highs, changes and price drops for Novonesis
Historical stock prices
Current Share Price	DKK 475.90
52 Week High	DKK 479.50
52 Week Low	DKK 274.60
Beta	0.52
11 Month Change	4.59%
3 Month Change	11.69%
1 Year Change	69.54%
33 Year Change	8.16%
5 Year Change	68.88%
Change since IPO	1,368.83%

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Shareholder Returns

	NSIS B	DK Chemicals	DK Market
7D	5.1%	2.0%	-2.8%
1Y	69.5%	14.6%	23.3%

Return vs Industry: NSIS B exceeded the Danish Chemicals industry which returned 14.6% over the past year.

Return vs Market: NSIS B exceeded the Danish Market which returned 23.3% over the past year.

Price Volatility

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	2.4%
Chemicals Industry Average Movement	5.0%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.2%
10% least volatile stocks in DK Market	2.5%

Stable Share Price: NSIS B has not had significant price volatility in the past 3 months.

Volatility Over Time: NSIS B's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	10,452	Ester Baiget	www.novonesis.com

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Novonesis A/S Fundamentals Summary

How do Novonesis's earnings and revenue compare to its market cap?
NSIS B fundamental statistics
Market cap	DKK 221.11b
Earnings (TTM)	DKK 2.11b
Revenue (TTM)	DKK 22.70b

104.9x

P/E Ratio

9.7x

P/S Ratio

Is NSIS B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NSIS B income statement (TTM)
Revenue	€3.04b
Cost of Revenue	€1.62b
Gross Profit	€1.42b
Other Expenses	€1.14b
Earnings	€282.79m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)	0.61
Gross Margin	46.66%
Net Profit Margin	9.29%
Debt/Equity Ratio	18.1%

How did NSIS B perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

108%

Payout Ratio

NSIS B Stock Overview

Rewards

Risk Analysis

Novonesis A/S Competitors

SHSE:600309

CN¥253.4b

NSEI:ASIANPAINT

₹3.1t

NYSE:PPG

US$29.8b

NYSE:DD

US$35.9b

Price History & Performance

Recent News & Updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Recent updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022